Program
elamipretide
Also written as “MTP-131”, “Elamipretide” and “Bendavia”.
Its studies are mostly in Heart Failure · Macular Degeneration · Mitochondrial Myopathies · Mitochondrial Diseases · Muscular Diseases, led by Mighty Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mighty Therapeutics | 273 open or running | phase 4since Mar 12, 2026 | Apr 30, 2010 | May 2027phase 1 · NCT07927972 |
Also a collaborator on its studies: icon-clinical-research.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Apr 30, 2010.
- Apr 30, 2015Phase 1 study in Renal InsufficiencyNCT02436447 · 23 enrolled · United States
- Feb 15, 2016Phase 2 study in Optic Atrophy, Hereditary, LeberNCT02693119 · 12 enrolled · United States
- May 27, 2016Phase 2 study in Heart FailureNCT02788747 · 71 enrolled · Italy, Netherlands, United Kingdom
- Jun 8, 20162 phase 2 studiesNCT02814097, NCT02805790
- Jul 25, 2016Phase 1 study in Macular DegenerationNCT02848313 · 40 enrolled · United States
- Sep 14, 2016Phase 2 study in Heart FailureNCT02914665 · 308 enrolled · Belgium, Bulgaria, France and more
- Nov 18, 2016Phase 2 study in Primary Mitochondrial DiseaseNCT02976038 · 28 enrolled · United States
- Mar 21, 2017Phase 3 study in Barth SyndromeNCT03098797 · 12 enrolled · United States
- Oct 12, 2017Phase 3 study in Muscular DiseasesNCT03323749 · 218 enrolled · United States, Canada, Denmark and more
- Mar 25, 2019Phase 2 study in Macular DegenerationNCT03891875 · 176 enrolled · United States
- Dec 8, 2021Phase 3 study in Mitochondrial MyopathiesNCT05162768 · 102 enrolled · United States, Australia, Germany and more
- Apr 16, 2024Phase 3 study in Macular DegenerationNCT06373731 · 313 enrolled · United States, Czechia, Germany and more
- Mar 12, 2026Phase 4 study in Barth SyndromeNCT07531251 · 48 planned · United States, Australia, Canada and more
- Oct 23, 2026Phase 1 study in Barth SyndromeNCT07927972 · 6 planned
Ahead
- May 2027Primary completion: phase 1 study in Barth SyndromeNCT07927972
- Aug 2027Primary completion: phase 3 study in Macular DegenerationNCT06373731
- Sep 30, 2029Primary completion: phase 4 study in Barth SyndromeNCT07531251
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07927972Barth Syndrome | 1 | Not yet recruiting | May 2027 | 6 |
| NCT07531251Barth Syndrome · United States, Australia, Canada and more | 4 | Recruiting | Sep 30, 2029 | 48 |
| NCT06373731Macular Degeneration · United States, Czechia, Germany and more | 3 | Active, not recruiting | Aug 2027 | 313 |
| NCT05162768Mitochondrial Myopathies · United States, Australia, Germany and more | 3 | Completed | Sep 30, 2024 | 102 |
| NCT03891875Macular Degeneration · United States | 2 | Completed | Feb 22, 2022 | 176 |
| NCT03323749Muscular Diseases · United States, Canada, Denmark and more | 3 | Terminated | Feb 10, 2020 | 218 |
| NCT03098797Barth Syndrome · United States | 3 | Completed | Oct 5, 2018 | 12 |
| NCT02976038Primary Mitochondrial Disease · United States | 2 | Terminated | Mar 9, 2020 | 28 |
| NCT02914665Heart Failure · Belgium, Bulgaria, France and more | 2 | Completed | Nov 27, 2017 | 308 |
| NCT02848313Macular Degeneration · United States | 1 | Completed | Mar 16, 2018 | 40 |
| NCT02805790Mitochondrial Myopathies · United States | 2 | Completed | Mar 10, 2017 | 30 |
| NCT02814097Heart Failure · Germany, Serbia | 2 | Completed | May 4, 2017 | 46 |
| NCT02788747Heart Failure · Italy, Netherlands, United Kingdom | 2 | Completed | Sep 2017 | 71 |
| NCT02693119Optic Atrophy, Hereditary, Leber · United States | 2 | Completed | Sep 2019 | 12 |
| NCT02436447Renal Insufficiency · United States | 1 | Completed | Jul 2015 | 23 |
| NCT02388529Heart Failure · Bulgaria | 1 | Withdrawn | Sep 2015 | 0 |
| NCT02388464Heart Failure · Bulgaria | 1 | Completed | Apr 2015 | 36 |
| NCT02367014Mitochondrial Myopathies · United States | 2 | Completed | Apr 2016 | 36 |
| NCT02314299Macular Degeneration · United States | 2 | Completed | May 2015 | 20 |
| NCT02245620Skeletal Muscle Mitochondrial Dysfunction in the Elderly · United States | 2 | Completed | Jul 6, 2016 | 41 |
| NCT01786915Healthy Volunteers · United States | 1 | Completed | Mar 2013 | 30 |
| NCT01755858Renal Artery Obstruction · United States | 2 | Terminated | Dec 2015 | 16 |
| NCT01754818Healthy · United States | 1 | Completed | Jan 2013 | 30 |
| NCT01572909Reperfusion Injury · United States, Germany, Hungary and more | 2 | Completed | Nov 2014 | 300 |
| NCT01518985Healthy Volunteers · United States | 1 | Completed | Mar 2012 | 6 |
| NCT01513200Healthy Volunteers · United States | 1 | Completed | Feb 2012 | 12 |
| NCT01115920Healthy · United States | 1 | Completed | Sep 2010 | 40 |
How it is read
Names in the registry
- “MTP-131”, 11 entries
- “Elamipretide”, 8 entries
- “elamipretide”, 4 entries
- “Bendavia”, 3 entries
- “Bendavia 10mg”, 2 entries
Conditions, from the studies’ own filings
- Heart Failure, 5 studies
- Macular Degeneration, 3 studies
- Mitochondrial Myopathies, 3 studies
- Mitochondrial Diseases, 2 studies
- Muscular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.